Third Wave Technologies, Inc.

Roche Sequencing Solutions, Inc.

Hoffmann-la Roche Inc.

Wisconsin Alumni Research Foundation

Northwestern University

Hologic, Inc.

Roche Nimblegen, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Victor I Lyamichev

Jeff G Hall

James E Dahlberg

Bruce P Neri

Mary Ann D Brow

James Robert Prudent

Hatim T Allawi

Mary Ann Brow

Michael W Kaiser

Fang Dong

Lance Fors

Jigar Patel

Robert W Kwiatkowski, Jr

LuAnne Chehak

Thomas J Albert

Andrew A Lukowiak

Andrea L Mast

Tsetska Y Takova

Zbigniev Skrzypczynski

Marilyn C Olson-Munoz

Sarah Olson

James J Schaefer

Lloyd M Smith

Natalie E Lyamicheva

Frank Bergmann

Michael Schraeml

Peggy S Eis

Hon Ip

Michelle Curtis

Christian Tor Bartholomay

WuPo Ma

Natasha Lyamicheva

Wojtek Steffen

Kevin L Vedvik

Lin Ji

Sarah R Wayland

Thomas Streidl

Lisa C Thompson

David Michael Olive

Brad T Argue

Todd A Anderson

Scott M Law

Stephanie H Vavra

Wu-Po Ma

Luanne Chehak

David M Kelso

Vecheslav A Elagin

Tobias Oelschlaegel

Priscilla Wilkins Stevens

Kwok Wu

Walter Iszczyszyn

Chris Fleming

Jeff Steven Hall

Mary C Oldenburg

Thomas Albert

Mohamed Yosry Hassan Mohamed

Michelle L Curtis

Hatim Taysir Allawi

Hon S Ip

Wupo Ma

Christian Klein

Ekkehard Moessner

Eric Charles Sullivan

Eric Argirios Kitas

David J Marshall

Brian Aizenstein

Poonam Agarwal

Robert W Kwiatkowski

Eric Sullivan

Per-Ola Freskgard

Ryan Bannen

Joerg Werner Baier

Hanying Li

Ken Lo

Sarah M Olson

Natalie E Lyamichev

Jeremy Beauchamp

Zbigniew Skrzypczynski

Ned D Reimer

Tatiani I Vener

Natalie Lyamichev

Eric B Rasmussen

David Arco

Myrta W Atiles

Deborah E Burris

Monika De Arruda Indig

Carolyn W Miller

Mary C Oldenberg

Jennifer M Schneiders

Zbigniew Skrzpczynski

Jeff Steven Grotelueschen Hall

Rex Piper

James L Dahlberg

Natasha Lyamichev

Lauren Goodrich

Nancy Jarvis

David Kurensky

Luis P Reynaldo

Michael Schaeml

Bruce N Neri

The disclosure provides compositions comprising at least one assembly comprising a peptide and a major histocompatibility complex (MHC), wherein the peptide is an integral component of the MHC, wherein the peptide is attached to a surface at its C-terminus through a linker and wherein the peptide is synthesized on the surface. In certain embodiments, the compositions comprise a plurality of assemblies in a spatially-ordered array. The disclosure provides methods for making and using these compositions.

MHC-bound peptide arrays and methods of use thereof

In one aspect, the present disclosure provides a system and method for the identification and characterization of a transglutaminase. Further, the present disclosure provides transglutaminase enzymes for forming isopeptide bonds, methods of forming isopeptide bonds in the presence of transglutaminases, and substrate tags for use with transglutaminases. In another aspect, the present disclosure provides glutamine-containing substrates (or Q-tag substrates) that are more resistant to proteases/clipping and therefore, more stable, than other Q-tag substrates, and their uses in substrate tags for cross-linking to an amine-donor tag via an isopeptide bond mediated by a microbial transglutaminase.

System and method for identification and characterization of transglutaminase species

According to one aspect, the present disclosure provides a method of identifying a substrate of a transglutaminase using a peptide array comprising a plurality of peptides. The method includes the steps of contacting the peptides in the peptide array with the transglutaminase, allowing the transglutaminase to bind to the peptides, and identifying the substrate of the transglutaminase.

Identification of transglutaminase substrates and uses therefor

The invention comprises systems, methods and arrays for identification and optimization of novel peptide binders to protein targets. Embodiments include steps of peptide binder discovery, core peptide maturation, N-terminal and C-terminal extension and kinetics analysis of the final peptide binder.

Systematic discovery, maturation and extension of peptide binders to proteins

The present invention relates to dual-site BACE1 inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

BACE1 inhibitor peptides

In one aspect, the present disclosure provides a system and method for the identification and characterization of a transglutaminase. Further, the present disclosure provides transglutaminase enzymes for forming isopeptide bonds, methods of forming isopeptide bonds in the presence of transglutaminases, and substrate tags for use with transglutaminases.

The invention provides novel peptide binders for streptavidin (SA), Taq polymerase and several human proteins: Prostate Specific Antigen (PSA), thrombin, Tumor Necrosis Factor Alpha (TNF&#x3b1;), and Urokinase-type Plasminogen Activator (uPA).

Specific peptide binders to proteins identified via systematic discovery, maturation and extension process

The present invention relates to compositions and methods for the detection and characterization of small nucleic acid molecules (e.g., RNA (e.g., small RNAs such as micro RNAs (miRNAs) and small interfering RNAs (siRNAs)) and other short nucleic acid molecules). More particularly, the present invention relates to methods for the detection and quantification of RNA expression. The present invention further provides for the detection of miRNA and siRNA variants.

Kits for detection of nucleic acids

The present invention provides systems, methods and kits for performing a detection assay (e.g., invasive cleavage assay) in combination with an amplification assay (e.g., PCR), where the detection assay employs enzyme footprint probes with relatively short (e.g., 6-12 bases) analyte-specific regions configured to provide a preferred footprint length of duplex for use with a particular nucleic acid modifying enzyme. In some embodiments, such assays are used for target quantification, and in other embodiments, such assays are used for genotyping. In certain embodiments, the use of such short probes allows for assays with increased dynamic range.

Methods for analysis of nucleic acid molecules during amplification reactions

The present invention relates to compositions and methods for the detection and characterization of interfering RNAs such as micro RNAs (miRNAs) and small interfering RNAs (siRNAs) and other short nucleic acid molecules. More particularly, the present invention relates to methods for the detection and quantitation of interfering RNA expression. The present invention further provides for the detection of variants and types of miRNAs and siRNAs.

Detection of small nucleic acids

The present invention relates to systems, methods and kits for low-level detection of nucleic acids, detecting at least two different viral sequences in a single reaction vessel, and increasing the dynamic range of detection of a viral target nucleic acid in a sample. The present invention also relates to T-structure invasive cleavage assays, as well as T-structure related target dependent non-target amplification methods and compositions. The present invention further relates to methods, compositions, devices and systems for consistent nucleic acid dispensing onto surfaces.

T-structure invasive cleavage assays, consistent nucleic acid dispensing, and low level target nucleic acid detection

The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof. The present invention further relates to methods and devices for the separation of nucleic acid molecules based on charge. The present invention also provides methods for the detection of non-target cleavage products via the formation of a complete and activated protein binding region. The invention further provides sensitive and specific methods for the detection of human cytomegalovirus nucleic acid in a sample.

Detection of nucleic acids by multiple sequential invasive cleavages

Growing community of inventors

Madison, WI, United States of America

Victor I Lyamichev